Metabolites: structure determination and prediction.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 24050243)

Published in Drug Discov Today Technol on January 01, 2013

Authors

Gabriele Cruciani

Articles by these authors

Computational approaches to identifying and characterizing protein binding sites for ligand design. J Mol Recognit (2010) 1.40

Tautomer enumeration and stability prediction for virtual screening on large chemical databases. J Chem Inf Model (2009) 1.39

Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J Med Chem (2003) 1.35

A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf Model (2007) 1.24

New and original pKa prediction method using grid molecular interaction fields. J Chem Inf Model (2007) 1.17

A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem (2011) 1.17

Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. J Med Chem (2004) 1.11

Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase. Proc Natl Acad Sci U S A (2012) 1.00

Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach. J Med Chem (2002) 0.95

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. J Med Chem (2005) 0.94

High-throughput virtual screening of proteins using GRID molecular interaction fields. J Chem Inf Model (2010) 0.93

Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev (2011) 0.92

GRID-based three-dimensional pharmacophores I: FLAPpharm, a novel approach for pharmacophore elucidation. J Chem Inf Model (2012) 0.91

Transporter-mediated Efflux Influences CNS Side Effects: ABCB1, from Antitarget to Target. Mol Inform (2010) 0.90

BDDCS class prediction for new molecular entities. Mol Pharm (2012) 0.89

Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series. Eur J Med Chem (2010) 0.89

Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition. J Chem Inf Model (2008) 0.89

The challenges of in silico contributions to drug metabolism in lead optimization. Expert Opin Drug Metab Toxicol (2010) 0.86

Calcium channel antagonists discovered by a multidisciplinary approach. J Med Chem (2006) 0.85

Modeling phospholipidosis induction: reliability and warnings. J Chem Inf Model (2013) 0.84

Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase. J Med Chem (2012) 0.83

Exposition and reactivity optimization to predict sites of metabolism in chemicals. Drug Discov Today Technol (2013) 0.83

A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J Med Chem (2005) 0.82

Surface descriptors for protein-ligand affinity prediction. J Med Chem (2003) 0.82

Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds. J Med Chem (2014) 0.82

Molecular fields in drug discovery: getting old or reaching maturity? Drug Discov Today (2009) 0.82

Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. J Med Chem (2010) 0.82

GRID-based three-dimensional pharmacophores II: PharmBench, a benchmark data set for evaluating pharmacophore elucidation methods. J Chem Inf Model (2012) 0.81

Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction. J Chem Inf Model (2010) 0.81

Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. J Med Chem (2013) 0.81

Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitors. Bioorg Med Chem (2010) 0.81

Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach. J Med Chem (2005) 0.80

On the catalytic role of the active site residue E121 of E. coli L-aspartate oxidase. Biochimie (2010) 0.80

Predictive models for hERG potassium channel blockers. Bioorg Med Chem Lett (2005) 0.79

Absolute configuration and biological profile of two thiazinooxadiazol-3-ones with L-type calcium channel activity: a study of the structural effects. Org Biomol Chem (2012) 0.79

Predicting protein pK(a) by environment similarity. Proteins (2009) 0.79

GRIND-derived pharmacophore model for a series of alpha-tropanyl derivative ligands of the sigma-2 receptor. J Comput Aided Mol Des (2004) 0.79

Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening. J Med Chem (2008) 0.78

Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opin Drug Metab Toxicol (2014) 0.78

Isozyme-specific ligands for O-acetylserine sulfhydrylase, a novel antibiotic target. PLoS One (2013) 0.77

Decoding the Structural Basis For Carbapenem Hydrolysis By Class A β-lactamases: Fishing For A Pharmacophore. Curr Drug Targets (2016) 0.77

Metabolism of JWH-015, JWH-098, JWH-251, and JWH-307 in silico and in vitro: a pilot study for the detection of unknown synthetic cannabinoids metabolites. Anal Bioanal Chem (2014) 0.77

BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity. Proteins (2015) 0.77

A new class of selective myocardial calcium channel modulators. 2. Role of the acetal chain in oxadiazol-3-one derivatives. J Med Chem (2005) 0.76

GBR compounds and mepyramines as cocaine abuse therapeutics: chemometric studies on selectivity using grid independent descriptors (GRIND). J Med Chem (2002) 0.76

Stereoselective behavior of the functional diltiazem analogue 1-[(4-chlorophenyl)sulfonyl]-2-(2-thienyl)pyrrolidine, a new L-type calcium channel blocker. J Med Chem (2009) 0.76

Targeting cystalysin, a virulence factor of treponema denticola-supported periodontitis. ChemMedChem (2014) 0.76

GRIND/ALMOND investigations on CysLT1 receptor antagonists of the quinolinyl(bridged)aryl type. Bioorg Med Chem (2004) 0.76

Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses. Antimicrob Agents Chemother (2012) 0.76

Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. J Med Chem (2004) 0.75

An innovative application of the "flexible" GRID/PCA computational method: study of differences in selectivity between PGAs from Escherichia coli and a Providentia rettgeri mutant. Biotechnol Prog (2004) 0.75

LC/MS lipid profiling from human serum: a new method for global lipid extraction. Anal Bioanal Chem (2014) 0.75

Interaction of DDSDEEN peptide with N-CAM protein. Possible mechanism enhancing neuronal differentiation. Peptides (2008) 0.75

Lipostar, a comprehensive platform-neutral cheminformatics tool for lipidomics. Anal Chem (2017) 0.75

Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach. J Med Chem (2004) 0.75

L-Type calcium channel blockers: from diltiazem to 1,2,4-oxadiazol-5-ones via thiazinooxadiazol-3-one derivatives. J Med Chem (2009) 0.75